Unit sale drives rise in Novartis Q1 net profits
AFP · 24 Apr 2014, 11:36
Published: 24 Apr 2014 11:36 GMT+02:00
- Pharma giants strike $16bn health-care deal (22 Apr 14)
- Indian drug rival denies Novartis patent charges (04 Apr 14)
- Top Novartis execs quit in Japan fraud scandal (03 Apr 14)
- Italy slaps Swiss pharma giants with huge fines (05 Mar 14)
The Basel-based company, which earlier this week announced an extreme make-over of its structure, said it recorded earnings of $2.96 billion during the first three months of the year.
Not counting acquisitions or other exceptional events such as the $900 million it booked during the quarter on the sale of its blood transfusion diagnostics unit to the Spanish firm Grifols, Novartis said its net profit remained flat year-on-year at $3.12 billion.
That was slightly higher than the £3.05 billion expected by analysts, according to a poll by Dow Jones Newswires.
The company meanwhile saw its net sales edge up just 1.0 percent during the quarter to $14.02 billion, missing analyst expectations it would rake in $14.22 billion.
Largely thanks to the diagnostics unit sale, announced last November, Novartis meanwhile saw its operating profit for the quarter soar 22 percent to $3.5 billion.
Investors appeared disappointed, sending Novartis's share price down 0.85 percent to 75.60 francs a piece in morning trading as the Swiss stock exchange's main SMI index rose 0.1 percent.
Novartis chief executive Joe Jimenez was upbeat, though.
"Novartis delivered a solid quarter, with all divisions contributing to growth," he said in the earnings statement, adding that going forward, things should only get better.
"The transformational deals announced on Tuesday position the company for future success based on our sharpened focus, innovation power and financial strength," he said.
He was referring to the unveiling of multi-billion-dollar deals with British GlaxoSmithKline and US group Eli Lilly, promising a major shake-up of the pharmaceutical sector.